MedPath

The Impact of Folic Acid in The Treatment of Major - Thalassemia

Not Applicable
Conditions
Beta Thalassemia.
Thalassemia(anemia) (disease)- major D56.1
Registration Number
IRCT2016011425989N2
Lead Sponsor
Vice chancellor for research, Guilan University ofMedical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Inclusion Criteria: Patients over Two Years of Age with Thalassemia Major Blood Recipient who Received Folic Acid Supplements for at Least 6 Months

Exclusion Criteria

Under two Years; Pregnant Women; Lactating Women

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum folic acid levels. Timepoint: Supplements before and one month after stopping it. Method of measurement: In terms of micrograms per liter and by chemiluminescence.;Serum homocysteine level. Timepoint: Supplements before and one month after stopping it. Method of measurement: In terms of micromoles per liter and by chemiluminescence.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath